More Time For NDI Guidance Comment: Health And Wellness Industry News Roundup

Testing lapse prompts Sammy's Milk recall; Hain Celestial solves UK trade authority puzzle; scheduling kratom impact calculated; and more news in brief.

FDA extends the comment period through Dec. 12 for its revised drat guidance on new dietary ingredient notifications it published in August, more than four years after it began revising the original draft met with widespread questions and criticism. The agency's Center for Food Safety and Applied Nutrition said in an Oct. 4 Federal Register notice that requests for 30- and 90-day extensions of the comment period "conveyed concern that the current 60-day comment period does not allow sufficient time for interested parties to develop a meaningful or thoughtful response to the draft guidance" and some "mentioned that the requests for comment may necessitate in-depth research and/or require supporting data to provide meaningful responses." CFSAN states that extending the comment period for 60 days from Oct. 11 – docket FDA-2011-D-0376 – should allow "adequate time for interested persons to submit comments without significantly delaying finalizing the guidance." (Also see "Revised NDI Notification Draft Guidance Shrinks Divide Between FDA And Industry" - HBW Insight, 12 August, 2016.)

Graceleigh Inc. recalls all lots of its Sammy’s Milk Baby Food because of possible presence of Cronobacter, a bacteria that can cause severe and sometimes fatal blood infections or meningitis in infants and because the product may not provide adequate nutritional levels of iron. The Newport Beach, Calif., firm on Sept. 30 it is conducting the voluntary recall following FDA’s determination that testing to confirm the absence of the bacteria was not performed and due to the absence of a label warning that it contains low iron and supplementation may be necessary, although the product meets FDA’s minimum requirement for iron content

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

Some Laid Off Employees Called Back At US FDA

 

Some FDA employees who were recently laid off by the Trump Administration are being called back to work, multiple sources confirmed to the Pink Sheet.

US Proposal To Remove Phenylephrine From OTC Monograph Could Stress-Test Streamlined Process

 

Proposed administrative order likely is first to prompt opposition from OTC industry or other stakeholders potentially delaying or deferring the agency’s expectation for moving its proposal to a deemed final order effective one year after it would be published.

FDA Clears Qnovia’s NRT Inhalation IND, Commits To ‘Stimulating’ Smoking Cessation Innovation

 

Qnovia notes NRT inhalation product recently received investigational new drug clearance from FDA as agency and NIH say innovation needed smoking cessation to help improve rate of success for quitting the habit that kills around 500,000 US consumers annually.

Washington State TFCA Violators Likely To Face Conversation Before Penalties – DOE

 

The Washington State Department of Ecology will try to work with companies that violate the Toxic Free Cosmetics Act, rather than reflexively imposing the $5,000-per-violation fine for first-time offenders, says the law’s implementation planner. She noted financial assistance is available for small businesses, as well as incentives for companies adopting measures “beyond compliance.”

More from North America

Washington State TFCA Violators Likely To Face Conversation Before Penalties – DOE

 

The Washington State Department of Ecology will try to work with companies that violate the Toxic Free Cosmetics Act, rather than reflexively imposing the $5,000-per-violation fine for first-time offenders, says the law’s implementation planner. She noted financial assistance is available for small businesses, as well as incentives for companies adopting measures “beyond compliance.”

Adcomm Reform: Getting Needed Information More Important Than Vote Or Discussion

 

US FDA Office of New Drugs Director Peter Stein says review divisions have made the case that a discussion-only meeting would solicit the necessary input.

US FDA’s Petition Procedures No Place For OTC Acetaminophen Pediatric Dosing Enforcement

 

Requests for “enforcement actions are not within the scope of FDA’s citizen petition procedures,” CDER says, rejecting petition dosing device firm Parenteral Technologies submitted as it prepares for workshop on Pediatric Research Equity Act requirements for OTC NDA sponsors.